ES2058350T3 - Mitogenos cerebrales de enlace de la heparina. - Google Patents

Mitogenos cerebrales de enlace de la heparina.

Info

Publication number
ES2058350T3
ES2058350T3 ES89101187T ES89101187T ES2058350T3 ES 2058350 T3 ES2058350 T3 ES 2058350T3 ES 89101187 T ES89101187 T ES 89101187T ES 89101187 T ES89101187 T ES 89101187T ES 2058350 T3 ES2058350 T3 ES 2058350T3
Authority
ES
Spain
Prior art keywords
brain
mitogens
heparin
hbbms
promotion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89101187T
Other languages
English (en)
Inventor
Peter Bohlen
Peter Gautschi-Sova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2058350T3 publication Critical patent/ES2058350T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Insulating Materials (AREA)
  • Insulated Conductors (AREA)
  • Dental Preparations (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA INVENCION SE REFIERE A UN GRUPO DE FACTORES DEL CRECIMIENTO, DESIGNADOS COMO MITOGENOS DEL CEREBRO QUE SE UNEN A LA HEPARINA, LOS CUALES SE AISLAN DEL TEJIDO CEREBRAL POR UNA SECUENCIA DE ETAPAS DE PURIFICACION. LOS FACTORES DEL CRECIMIENTO PUEDEN SER UTILES EN LA PROMOCION DE ANGIOGENESIS, TALES COMO PROMOCION DE QUEMADURAS, ASI COMO PARA PROMOVER LA FORMACION, MANTENIMIENTO Y REPARACION DE TEJIDOS, EN PARTICULAR DE TEJIDOS NERVIOSOS.
ES89101187T 1988-01-25 1989-01-24 Mitogenos cerebrales de enlace de la heparina. Expired - Lifetime ES2058350T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14783588A 1988-01-25 1988-01-25

Publications (1)

Publication Number Publication Date
ES2058350T3 true ES2058350T3 (es) 1994-11-01

Family

ID=22523098

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89101187T Expired - Lifetime ES2058350T3 (es) 1988-01-25 1989-01-24 Mitogenos cerebrales de enlace de la heparina.

Country Status (9)

Country Link
EP (1) EP0326075B1 (es)
JP (1) JPH01308300A (es)
AT (1) ATE94882T1 (es)
AU (1) AU624803B2 (es)
DE (1) DE68909254T2 (es)
DK (1) DK29889A (es)
ES (1) ES2058350T3 (es)
FI (1) FI890342A (es)
NO (1) NO175594C (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US6448381B1 (en) * 1990-01-08 2002-09-10 Barnes-Jewish Hospital DNA encoding heparin-binding growth factor
ES2104686T3 (es) * 1990-04-12 1997-10-16 Ebewe Arzneimittel Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.
FR2665448A1 (fr) * 1990-08-01 1992-02-07 Paris Val De Marne Universite Procede d'obtention d'un peptide ayant une activite facteur de croissance, produit obtenu et son application comme medicament.
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
EP0535337A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Cell growth inhibiting activities of heparin binding neurite-outgrowth promoting factor
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
FI980032A0 (fi) * 1998-01-09 1998-01-09 Heikki Matti Eemeli Rauvala Ny anvaendning av en heparin bindande, med tillvaext foerknippad molekyl
US6364912B1 (en) 1999-09-17 2002-04-02 Depuy Orthopeaedics, Inc. Pleiotrophin-based compositions for enhancing connective tissue repair
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248088A4 (en) * 1985-11-22 1988-05-03 Teijin Ltd VASCULARIZATION FACTOR AND MANUFACTURING.
EP0241136A3 (en) * 1986-03-07 1989-12-27 The President And Fellows Of Harvard College Human class 1 heparin-binding growth factor
CA2005600A1 (en) * 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor

Also Published As

Publication number Publication date
EP0326075A2 (en) 1989-08-02
FI890342A (fi) 1989-07-26
AU624803B2 (en) 1992-06-25
DK29889D0 (da) 1989-01-24
EP0326075A3 (en) 1989-10-18
DK29889A (da) 1989-07-26
EP0326075B1 (en) 1993-09-22
DE68909254D1 (de) 1993-10-28
NO890295D0 (no) 1989-01-24
NO175594B (no) 1994-07-25
AU2873789A (en) 1989-07-27
JPH01308300A (ja) 1989-12-12
DE68909254T2 (de) 1994-04-28
NO890295L (no) 1989-07-26
NO175594C (no) 1994-11-02
ATE94882T1 (de) 1993-10-15
FI890342A0 (fi) 1989-01-24

Similar Documents

Publication Publication Date Title
DK0429570T3 (da) Osteoinducerende præparater
ATE259420T1 (de) Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12)
ES2058350T3 (es) Mitogenos cerebrales de enlace de la heparina.
IT1214505B (it) Procedimento per la preparazione di collageno e prodotti cosi'ottenuto.
ES2152998T3 (es) Agente anticomplementario obtenido a partir de fucanos de algas pardas.
GR3026751T3 (en) Process for producing collagen fibres
DK0386793T3 (da) 1alfa-hydroxyvitamin D2 epimer og derivater heraf
ATE221083T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
ATE79115T1 (de) Antiinflammatorisch wirkende furanone.
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
SE8104482L (sv) Forfarande for framstellning av ett faktor viii (ahf)-hogkoncentrat
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
EP0241136A3 (en) Human class 1 heparin-binding growth factor
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
IT1225483B (it) Protesi ortopedica, particolarmente per la testa del femore.
IT9022257A0 (it) Macchina per la manutenzione del binario, per il trattamento della massicciata di binari ferroviari
ATE99687T1 (de) Strobilurinderivate, ihre herstellung und verwendung.
DE3851696D1 (de) Faktor VIII- Gelfiltration.
DE3784308D1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DE69331231D1 (de) Ein neuartiges, antineoplastisches cytokin
RU93037867A (ru) Способ лечения длительно незаживающих ран и трофических язв кожных покровов
RU95119300A (ru) Средство для лечения длительно незаживающих ран

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 326075

Country of ref document: ES